526 related articles for article (PubMed ID: 18037561)
21. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.
Oberg K
Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573
[TBL] [Abstract][Full Text] [Related]
22. The somatostatin receptor subtype 5 in neuroendocrine tumours.
van der Hoek J; Lamberts SW; Hofland LJ
Expert Opin Investig Drugs; 2010 Mar; 19(3):385-99. PubMed ID: 20151855
[TBL] [Abstract][Full Text] [Related]
23. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours.
Modlin IM; Pavel M; Kidd M; Gustafsson BI
Aliment Pharmacol Ther; 2010 Jan; 31(2):169-88. PubMed ID: 19845567
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.
Oberg K
Ann Oncol; 2001; 12 Suppl 2():S111-4. PubMed ID: 11762335
[TBL] [Abstract][Full Text] [Related]
25. [Somatostatin analogs in oncology].
Thomas F; Parmar H; Prevost G; Kuhn JM; Bejot JL; Moreau JP; Bogden A
Bull Cancer; 1991; 78(8):693-707. PubMed ID: 1681967
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy of somatostatin analogues in the treatment of neuroendocrine tumours based on the results of recent clinical trials].
Igaz P
Orv Hetil; 2014 Nov; 155(48):1908-12. PubMed ID: 25417137
[TBL] [Abstract][Full Text] [Related]
27. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
Arnold R; Simon B; Wied M
Digestion; 2000; 62 Suppl 1():84-91. PubMed ID: 10940693
[TBL] [Abstract][Full Text] [Related]
28. [Gastroenteropancreatic neuroendocrine tumours (carcinoid tumours): definition, clinical aspects, diagnosis and therapy].
Bodelier AG; Haak HR
Ned Tijdschr Geneeskd; 2006 Aug; 150(34):1868-72. PubMed ID: 16970007
[TBL] [Abstract][Full Text] [Related]
29. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules.
Massironi S; Conte D; Rossi RE
Scand J Gastroenterol; 2016; 51(5):513-23. PubMed ID: 26605828
[TBL] [Abstract][Full Text] [Related]
30. Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment.
Janson ET; Oberg K
Cancer Chemother Biol Response Modif; 2003; 21():535-46. PubMed ID: 15338762
[No Abstract] [Full Text] [Related]
31. Biotherapies for GEP-NETs.
Öberg K
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):833-41. PubMed ID: 23582922
[TBL] [Abstract][Full Text] [Related]
32. A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours.
Stronge RL; Turner GB; Johnston BT; McCance DR; McGinty A; Patterson CC; Ardill JE
Ann Clin Biochem; 2008 Nov; 45(Pt 6):560-6. PubMed ID: 18782815
[TBL] [Abstract][Full Text] [Related]
33. Advances in chemotherapy and biotherapy of endocrine tumors.
Oberg K
Curr Opin Oncol; 1998 Jan; 10(1):58-65. PubMed ID: 9466486
[TBL] [Abstract][Full Text] [Related]
34. Radioguided surgery and systemic radionuclide therapy of neuroendocrine tumours.
Hodolic M; Fettich J; Marzola MC; Tonini E; Al-Nahhas A; Rubello D
In Vivo; 2010; 24(1):97-100. PubMed ID: 20133983
[TBL] [Abstract][Full Text] [Related]
35. Function and expression of somatostatin receptors of the endocrine pancreas.
Strowski MZ; Blake AD
Mol Cell Endocrinol; 2008 May; 286(1-2):169-79. PubMed ID: 18375050
[TBL] [Abstract][Full Text] [Related]
36. [Drug therapy for neuroendocrine tumours].
Tóth M
Orv Hetil; 2013 Sep; 154(39):1556-64. PubMed ID: 24058101
[TBL] [Abstract][Full Text] [Related]
37. Neuroendocrine tumors. Peptide receptor radionuclide therapy.
Forrer F; Valkema R; Kwekkeboom DJ; de Jong M; Krenning EP
Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):111-29. PubMed ID: 17382268
[TBL] [Abstract][Full Text] [Related]
38. Somatostatin analogue treatment of neuroendocrine tumours.
de Herder WW; van der Lely AJ; Lamberts SW
Postgrad Med J; 1996 Jul; 72(849):403-8. PubMed ID: 8935599
[TBL] [Abstract][Full Text] [Related]
39. Hypoglycemia induced by long-acting somatostatin analogues in a patient with nonfunctional neuroendocrine tumor.
Unek IT; Celtik A; Yener S; Yavuzsen T; Alacacioglu A; Cokmert S; Oztop I; Demirkan B; Dicle O; Sagol O; Bekis R; Yilmaz U
J BUON; 2009; 14(1):135-8. PubMed ID: 19365885
[TBL] [Abstract][Full Text] [Related]
40. Future aspects of somatostatin-receptor-mediated therapy.
Oberg K
Neuroendocrinology; 2004; 80 Suppl 1():57-61. PubMed ID: 15477719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
